UFP Technologies, Inc. (UFPT) Seasonal Returns Chart
This article from Yahoo Finance provides a seasonal returns chart for UFP Technologies, Inc. (UFPT). It displays the average monthly price return for the company's stock between 2016 and 2026. The current stock price for UFPT is also shown, along with its daily change.
UFP Technologies Inc. Data Breach
Federman & Sherwood is investigating a data breach at UFP Technologies Inc. following a notification filed with the California Attorney General. The incident, reported on November 5, 2026, may have compromised sensitive personal information such as names and Social Security numbers. The law firm is examining whether UFP Technologies Inc. implemented adequate cybersecurity safeguards to protect customer data.
UFP Technologies, Inc. (UFPT) Seasonal returns chart
This article provides a seasonal returns chart for UFP Technologies, Inc. (UFPT), displaying the average monthly price return between 2016 and 2026. It includes current stock data such as the delayed quote, current price, and after-hours trading information. The page also features links to related tickers and various market data.
UFP Technologies 3Q 2026: Revenue $172.43M, EPS $2.64 — 10-Q Summary
UFP Technologies reported increased net sales and earnings for the third quarter of 2026, driven by growth in several medical market segments. The company saw an 11.6% rise in net sales to $172.43M and a 25.1% increase in diluted EPS to $2.64, with medical sales constituting 92.9% of total net sales. Operating efficiencies and a recent acquisition also contributed to improved gross margin.
UFP Technologies eyes more medical injection molding acquisitions
UFP Technologies plans to pursue additional acquisitions to support its growth strategy, particularly in the medical injection molding sector. The company's focus on M&A is highlighted as a key driver for future expansion. This article also mentions broader resin market trends and price forecasts.
Earnings Beat Might Change The Case For UFP Technologies Stock (UFPT)
UFP Technologies (UFPT) reported strong third-quarter 2026 earnings, with sales of US$172.43 million and net income of US$20.62 million, exceeding prior-year figures. These results support the company's operating thesis of scaling medical-focused manufacturing while maintaining profitability. While the earnings beat reinforces the investment narrative, risks from customer concentration, labor issues, and cost inflation still need to be monitored.
GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare shares skyrocket, what you need to know
Shares of GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare surged following election results that confirmed Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty in the biopharmaceutical sector. Analysts project a strengthened recovery for the industry as drug pricing legislation is unlikely to dominate the new legislative agenda, fostering a predictable regulatory climate. UFP Technologies, in particular, saw a significant jump of 21.5%, contributing to its 51.1% year-to-date increase.
UFP Technologies stock hits 52-week high at $338.86
UFP Technologies Inc. (UFPT) stock reached a new 52-week high of $338.86, currently trading at $340.91 with a market capitalization of $2.61 billion. The company has seen significant growth, with a 46% return over six months and a 42.87% increase over the past year. Despite this performance, InvestingPro data suggests the stock is overvalued, trading at a P/E ratio of 35.77.
Sales rise 11.6% at UFP Technologies (UFPT), with Q3 profit growing faster.
UFP Technologies (UFPT) reported strong third-quarter 2026 results, with net sales increasing by 11.6% to $172.4 million and net income rising 25.8% to $20.6 million. The company's MedTech sales also grew by 12.5%, and it announced investments in additional capacity at DAS Medical and progress on acquisition opportunities. Despite some operational challenges related to Dominican Republic program transfers, UFP Technologies expressed optimism for 2027.
UFPT Q3 2026 deep dive: broad-based MedTech growth and acquisition strategy drive results
UFP Technologies (UFPT) exceeded Wall Street's revenue and profit expectations in Q3 2026, driven by robust organic growth across its MedTech portfolio, especially in patient beds, cardiovascular, infection control, and orthopedics. The company attributes its success to operational improvements and strategic investments, including the acquisition of CI Medical and an active M&A pipeline. Management anticipates continued double-digit growth, supported by expanded manufacturing capacity and ongoing operational efficiencies, particularly with the AJR offshore transition.
UFP Technologies (NASDAQ:UFPT) Shares Gap Up After Strong Earnings
UFP Technologies (NASDAQ:UFPT) shares gapped up after the company reported stronger-than-expected quarterly earnings, with EPS of $2.88 against a $2.49 consensus and revenue of $172.43 million exceeding expectations. Despite the positive earnings, analyst sentiment remains mixed with an average "Hold" rating, and insiders sold a significant number of shares in the last quarter. Institutional investors, however, have significantly increased their positions in the company.
UFP Technologies Q3 2026 Earnings Call Transcript
UFP Technologies reported strong third-quarter 2026 financial results, with sales up 11.6% to $172.4 million and adjusted EPS rising to $2.88. The company highlighted broad growth across its MedTech segment, strategic acquisitions like CI Medical, and plans to expand its credit facility for future inorganic growth. Management expressed optimism for 2027, focusing on continued customer relationships, expanded capabilities, and disciplined growth, while acknowledging areas for operational improvement, particularly the ongoing AJR transfer to the Dominican Republic.
UFP Technologies Q3FY26 Results: Net income up 25.8% to $20.6 million
UFP Technologies reported a 25.8% year-over-year increase in net income, reaching $20.6 million for Q3FY26, with net sales climbing 11.6% to $172.4 million. The growth was primarily driven by strong MedTech demand, which saw a 12.5% sales increase in the quarter, and an expanded gross margin of 29.4%. Despite a rise in SG&A expenses, the company remains optimistic about future growth, planning capacity expansions and pursuing acquisition opportunities.
UFP Technologies (NASDAQ:UFPT) Announces Quarterly Earnings Results, Beats Estimates By $0.39 EPS
UFP Technologies (NASDAQ:UFPT) announced strong quarterly earnings, reporting $2.88 EPS, significantly beating the consensus estimate of $2.49, with revenues also exceeding expectations. Despite the positive earnings, shares experienced a slight decline in Tuesday trading. Insider selling activity was noted, while analysts maintained a "Hold" consensus rating for the stock.
UFP Technologies (NASDAQ:UFPT) Posts Inline Q3 Revenue and Clear EPS Beat Amid Cautious Trading
UFP Technologies (NASDAQ:UFPT) reported third-quarter 2026 results that showed inline revenue but a clear beat on adjusted EPS. Despite the positive earnings surprise, the stock's recent price action suggests investors remain cautious, with shares having fallen significantly in the weeks prior to the earnings release. Management highlighted strong MedTech demand but also noted that program transfers and margin improvement initiatives are behind schedule, and SG&A costs are rising.
UFP Technologies (NASDAQ:UFPT) delivers impressive Q3 2026
UFP Technologies (NASDAQ:UFPT) reported strong Q3 2026 results, with revenue of $172.4 million exceeding expectations by 3.2% and non-GAAP EPS of $2.88 beating estimates by 7.3%. The company highlighted operational improvements, successful investments, and continued scaling of new programs. Despite a projected deceleration in revenue growth, analysts expect solid performance moving forward.
UFP Technologies (NASDAQ:UFPT) delivers impressive Q3 2026
UFP Technologies (NASDAQ:UFPT) reported impressive Q3 2026 results, with revenue of $172.4 million exceeding Wall Street expectations and non-GAAP profit of $2.88 per share beating consensus estimates. The company showed strong long-term revenue and EPS growth, driven by effective cost management and strategic investments. Despite a projected deceleration in revenue growth, analysts expect continued success for its newer products and services.
UFP Technologies Announces Strong Q3 Results
UFP Technologies, Inc. (Nasdaq: UFPT) reported strong financial results for its third quarter ended September 30, 2026, with net income increasing 25.8% to $20.6 million and net sales growing 11.6% to $172.4 million. The company highlighted solid execution, 11.1% organic growth, and significant improvements in MedTech sales and gross margins, while also outlining strategic investments and expansion plans for 2027.
UFP Technologies (UFPT) Q3 earnings report preview: what to look for
UFP Technologies (NASDAQ: UFPT) is set to announce its Q3 earnings results, with analysts expecting an 8.1% year-on-year revenue growth. The medical products company has a history of beating revenue expectations but has also missed Wall Street's estimates multiple times in the past two years. Investors will be watching closely as other drug development inputs & services segment peers have shown mixed results.
UFP TECHNOLOGIES INC. R (UFP.HM) Seasonal returns chart
The article provides a seasonal returns chart for UFP Technologies Inc. R (UFP.HM). It states that seasonality data is currently unavailable for this ticker. The company's Q3 2026 earnings call is scheduled for November 4, 2026, at 2:30 pm GMT+1.
Do UFP Technologies' (NASDAQ:UFPT) Earnings Warrant Your Attention?
UFP Technologies' shares have gained 42% over the last five years, outperforming its earnings per share growth of 18% per year. The company's impressive revenue growth and strong net income growth are positive indicators, although its low return on equity suggests less efficient profit generation from shareholder capital compared to some peers. Despite this, UFP Technologies appears to be a company worth further investigation.
UFP Technologies to Report Third Quarter 2026 Financial Results on November 3, 2026
UFP Technologies, Inc. announced it will release its third-quarter 2026 financial results on Tuesday, November 3rd, after the close of the stock market. The company will host a conference call the following day, November 4th, at 8:30 AM ET, to discuss these results. Interested parties can access the call via dial-in numbers or a live webcast.
UFP Technologies (UFPT) Expected to Release Quarterly Earnings on Monday
UFP Technologies (UFPT) is expected to report its Q3 2026 earnings after market close on Monday, November 2nd, with analysts forecasting $2.49 EPS on $166.89 million in revenue. This follows a strong previous quarter where the company surpassed expectations with $2.92 EPS and $173.96 million in revenue. Despite a consensus "Hold" rating from analysts, insiders have recently sold over $8.17 million worth of stock.
UFP Technologies, Inc. Estimates – NASDAQ:UFPT
This article provides an overview of UFP Technologies, Inc. (NASDAQ: UFPT) financial data and analyst estimates available on TradingView. It encourages users to explore reported financial data, compare actual results with estimates, and visualize trends across income statements, balance sheets, cash flow statements, and valuation metrics. The content explicitly states that it is not investment advice and urges users to conduct their own research.
UFP Technologies, Inc. (UFPT) Stock forecasts
Argus has lowered its target price for UFP Technologies Inc. (UFPT) to $327.00, citing the company's focus on designing and manufacturing components, subassemblies, products, and packaging for the medical market. The stock's current price is $297.33. The report was published on October 21, 2026.
Argus lowers target for UFP Technologies stock to USD 331.00
Argus has lowered its price target for UFP Technologies (UFPT) stock to USD 331.00, while maintaining a bullish rating. This adjustment comes after the company reported second-quarter 2026 revenue of USD 173.96 million, exceeding analyst consensus. The stock traded at EUR 261.80 on October 20, 2026, with the next quarterly results expected on November 4, 2026.
UFP Technologies meets KeyBanc before November 4 results for UFP Technologies stock
UFP Technologies met with KeyBanc on October 15, ahead of its Q3 2026 earnings report scheduled for November 4. The company previously reported strong Q2 revenues of USD 173.96 million, surpassing consensus estimates, and recently acquired CI Medical to expand its medical device capabilities. Investors will be watching the upcoming report to see if this positive momentum continued into the third quarter.
UFP Technologies, Inc. (UFPT) stock forecast and price target
This article provides an in-depth analysis of UFP Technologies, Inc. (UFPT) stock forecast and price targets based on analyst recommendations. It details various price target adjustments, both increases and decreases, along with maintained ratings, primarily from Argus within the Healthcare sector. The data covers a period from April 2026 to October 2026, offering insights into the evolving analyst sentiment for UFPT.
KeyBanc hosts UFP Technologies meeting as UFP Technologies stock costs EUR 260.20
KeyBanc hosted meetings with UFP Technologies management on October 14-15, 2026, where the company's strong second-quarter revenue of USD 173.96 million and adjusted EPS of USD 2.92 were discussed. The stock is currently trading at EUR 260.20 with a market capitalization of USD 2.3 billion, and these meetings provide investors with an updated operational checkpoint. The focus for future updates will be on execution and capacity utilization following the positive earnings.
WASATCH ADVISORS LP Trims UFP Technologies Inc (UFPT) Stake -- S
WASATCH ADVISORS LP reduced its stake in UFP Technologies Inc (UFPT) by 19.09% on September 30, 2026, selling 130,453 shares at $296.82 each. The firm, which still holds 552,809 shares of UFPT, made this move as the stock appears "Fairly Valued" with a GF Value of $278.17 compared to its current price of $291.10. UFP Technologies, a medical device manufacturer with strong fundamentals and growth, has seen its stock appreciate significantly since its IPO, leading to this measured portfolio adjustment by WASATCH ADVISORS LP.
(UFPT) Price Dynamics and Execution-Aware Positioning
Ufp Technologies Inc. (NASDAQ: UFPT) is exhibiting weak near-term sentiment despite long-term strength, with a mid-channel oscillation pattern identified. AI models have generated three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss parameters. The analysis highlights an exceptional 50.3:1 risk-reward setup targeting a 14.5% gain against a 0.3% risk.
One investment adviser reports a 7.1% passive stake in UFP Technologies (UFPT).
Wasatch Advisors has reported a 7.1% passive stake in UFP Technologies (UFPT) through an amended SCHEDULE 13G/A filing. The investment adviser holds sole voting authority over 363,292 shares and sole dispositive authority over 552,809 shares. This filing indicates Wasatch Advisors' beneficial ownership of 552,809 common shares in UFP Technologies.
Congress Asset Management Co. Cuts Stock Position in UFP Technologies, Inc. $UFPT
Congress Asset Management Co. reduced its stake in UFP Technologies (NASDAQ:UFPT) by 15.8% in the third quarter, selling 108,669 shares and retaining 578,770 shares valued at approximately $171.8 million. Despite the reduction, UFP Technologies still constitutes 1.1% of the firm's holdings, making it its 16th largest position, with institutional investors owning 87.28% of the company. The company reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, though the stock has a consensus "Hold" rating from analysts.
Q2 Earnings Roundup: UFP Technologies (NASDAQ:UFPT) And The Rest Of The Drug Development Inputs & Services Segment
The article provides a Q2 earnings roundup for the drug development inputs & services segment, highlighting UFP Technologies (NASDAQ:UFPT) as a strong performer. It discusses key industry trends, such as increasing investment in biologics and outsourcing, as well as potential headwinds like pricing pressures. The report also details the performance of other companies in the sector, including Azenta, IQVIA, Charles River Laboratories, and Repligen.
UFP Technologies stock gained 1.94 percent on October 2
UFP Technologies (UFPT) stock rose 1.94% to USD 300.70 on October 2, 2026. The company reported strong Q2 2026 results, with revenue of USD 173.96 million and adjusted EPS of USD 2.92, both exceeding analyst consensus estimates. Analysts maintain an Outperform rating with an average price target of USD 355.00, suggesting further upside despite the stock being below its 52-week high.
(UFPT) Risk Channels and Responsive Allocation
This article provides a quantitative analysis of Ufp Technologies Inc. (NASDAQ: UFPT), identifying a near-term neutral sentiment amidst mid and long-term strength. It details specific trading strategies for different risk profiles, including long, breakout, and short positions, along with support and resistance levels across multiple timeframes. The analysis highlights an exceptional risk-reward short setup targeting 13.0% downside.
Return on invested capital % of UFP Technologies, Inc. – HAN:UFP
This article displays the "Return on invested capital %" for UFP Technologies, Inc. (HAN:UFP). The content indicates that for the specified period, the value is present along with its change and percentage change. It appears to be a financial data point provided by TradingView.
UFP Technologies stock builds on record second quarter results
UFP Technologies (UFPT) reported strong second-quarter 2026 results, with revenue increasing 15.10% year-over-year to $173.96 million and adjusted EPS reaching $2.92, exceeding consensus estimates. The medical-device manufacturer's net income also rose significantly, and its market capitalization stands at $2.3 billion. The company continues to show growth in specialized healthcare manufacturing.
UFP Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for UFP Technologies, Inc. (UFP) based on analyst opinions, including maximum and minimum price estimates for 2027. It details financial information such as past earnings and revenue, upcoming earnings dates, and current EBITDA, while also clarifying that the content is not investment advice.
Is UFP Technologies Inc (UFPT) Overvalued After 3.9% Rally? GF V
UFP Technologies Inc (UFPT) rallied 3.9%, reaching $298.48, but GuruFocus' GF Value™ indicates it is 7.8% overvalued with a fair value of $276.93. Despite a strong GF Score™ of 96/100 and high growth potential, the stock's current P/E ratio is higher than its historical median, and significant insider selling suggests caution. Investors are advised to consider the limited upside potential and potential downside risk due to its overvaluation.
UFP Technologies, Inc. (UFPT) Stock Forecasts
Argus has raised its target price for UFP Technologies, Inc. (UFPT) to $321.00. The company, which is a designer and custom manufacturer of components for the medical market, currently has a stock price of $295.65. This update is part of a series of research reports from Argus.
UFP Technologies, Inc. $UFPT Shares Newly Bought by Bank of America Corp DE
Bank of America Corp DE recently acquired 60,312 shares of UFP Technologies (NASDAQ:UFPT) worth approximately $15.99 million in the second quarter. This move makes Bank of America a significant institutional holder, with institutional investors collectively owning 87.28% of the company. Despite recent insider selling, UFP Technologies reported strong Q2 earnings, beating analyst estimates, and analysts maintain an overall "Hold" rating for the stock.
Labor Problems Pressured UFP Technologies (UFPT)
Tributary Capital Management's Q2 2026 investor letter for its Multi Cap Core Equity Strategy highlighted UFP Technologies (UFPT), noting that labor problems are slowing production, lowering sales, and raising costs for the company. Despite UFP Technologies' stock being up significantly over the past year, it underperformed in the second quarter. The strategy suggests that other AI stocks offer greater upside potential with less risk compared to UFPT.
UFP Technologies (NASDAQ:UFPT) Stock Passes Above 200-Day Moving Average - What's Next?
UFP Technologies (NASDAQ:UFPT) saw its stock price rise above its 200-day moving average, reaching $288.44 and closing at $285.20. The company exceeded quarterly earnings expectations with an EPS of $2.92 and revenue of $173.96 million. Despite an overall "Hold" rating from analysts, some insiders have sold shares totaling approximately $8.17 million over the last 90 days.
Exit valuation: Welch Fluorocarbon acquired by UFP Technologies for $34.6M (SEC)
UFP Technologies has acquired Welch Fluorocarbon for $34.6 million in cash, with potential additional contingent consideration of up to $6.0 million. The acquisition, completed on July 15, 2024, integrates Welch Fluorocarbon, a developer of implantable medical device components, into UFP Technologies. The information regarding the acquisition was sourced from UFP Technologies' FY2024 10-K annual report.
UFP Technologies, Inc. $UFPT Shares Bought by California State Teachers Retirement System
The California State Teachers Retirement System significantly increased its stake in UFP Technologies (NASDAQ:UFPT) by over 25,000% in Q2, acquiring an additional 2.36 million shares, bringing their total ownership to approximately 30.54% valued at $627.4 million. Other institutional investors also raised their positions, with institutions collectively owning 87.28% of the company, despite some insider selling. UFP Technologies also reported strong Q2 earnings, surpassing analyst estimates with $2.92 EPS and $173.96 million in revenue.
Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies
This Zacks Industry Outlook highlights Veracyte, Globus Medical, and UFP Technologies as well-positioned to benefit from the increasing adoption of Generative AI (GenAI) in the Medical Instruments industry. The article discusses key trends shaping the industry, including the GenAI revolution, ongoing M&A activity, and global economic disruptions. It also provides a detailed analysis of the three companies, noting their strong growth prospects and Zacks Ranks.
UFP Technologies (Nasdaq:UFPT) - Stock Analysis
This Simply Wall St analysis provides an overview of UFP Technologies (UFPT), highlighting its market performance, financial health, and future growth prospects. The report notes significant insider selling, recent acquisitions like CI Medical Inc., and leadership changes aimed at strengthening its medical device focus. It also includes analyst price targets and a summary of recent news and updates affecting the company's stock.
Implied Volatility Surging for UFP Technologies Stock Options
Implied volatility for UFP Technologies (UFPT) stock options is surging, particularly for the Oct. 16, 2026 $200.00 Put, indicating expectations of a significant price movement. Despite the high implied volatility, analysts currently rate UFP Technologies as a Zacks Rank #2 (Buy) in the Medical - Instruments industry, although recent earnings estimates have seen a slight downward revision. This situation suggests a potential trading opportunity, especially for options traders looking to sell premium.
The Manufacturers Life Insurance Company Buys Shares of 3,732 UFP Technologies, Inc. $UFPT
The Manufacturers Life Insurance Company recently acquired 3,732 shares of UFP Technologies (NASDAQ:UFPT) valued at approximately $989,000. This purchase comes as institutional investors now hold 87.28% of the company, while insiders have been selling shares totaling over $8.46 million in the last three months. UFP Technologies has reported strong quarterly earnings, beating analyst expectations for both EPS and revenue, though the stock maintains a consensus "Hold" rating despite one recent upgrade.